Magenta Therapeutics’ MGTA-117 blood cancer clinical trial has gone from bad to worse. Weeks after Magenta dropped down a dose level in response to serious adverse events (SAEs), a patient has died ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback